9th Jul 2015 08:25
LONDON (Alliance News) - Life sciences company OptiBiotix Health PLC on Thursday said it has signed a deal with the Instituto de Química Orgánica General, part of the Spanish Research Council in Madrid.
Under the deal, OptiBiotix and the institute will work on progressing the company's pipeline of novel oligosaccharides, carbohydrates that consists of a small number of sugars, which have been identified as candidates for human testing.
"The last few months have seen substantial progress in reducing the technical risks associated with this exciting programme designed to create low calorie, sweet oligosaccharides, which could be used to reduce chronic lifestyle disease such as heart disease, obesity and diabetes," said Stephen O'Hara, OptiBiotix's chief executive.
"We are particularly pleased that international commercial partners have recognised the opportunity presented by this work and are including their own strains in the final stages of this development programme," O'Hara added.
Shares in OptiBiotix were down 5.3% to 34.57 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
OptiBiotix Health